FDA: Boosters for those high risk, seniors
An influential panel of advisers to the Centers for the Disease Control and Prevention convened on Wednesday to debate which Americans should get COVID-19 booster shots and when – a question that has proved more contentious than the Biden administration apparently expected.
The meeting came days after a different advisory group – this one serving the Food and Drug Administration – overwhelmingly rejected a sweeping White House plan to dispense third shots to nearly everyone. Instead, that panel endorsed booster doses of the Pfizer vaccine only for senior citizens and those at high risk from the virus.
While the COVID-19 vaccines continue to offer strong protection against severe illness, hospitalization and death, immunity against milder infection seems to be dropping months after vaccination.
Last week’s FDA advisory panel decision was only the first hurdle as the government sets its booster policy. The FDA itself still has to decide whether it agrees with its advisers’ recommendation and will authorize Pfizer boosters.
If it does, the CDC then must recommend who should get the extra shots after hearing from its own Advisory Committee on Immunization Practices, whose meeting was scheduled to extend into Thursday.
The priority still is to vaccinate the unvaccinated, who the CDC says account for the vast majority of COVID-19 cases, now soaring to levels not seen since last winter. About 182 million Americans are fully vaccinated, nearly 55% of the total population.
Much of the deliberation at the meeting was expected to be about who is considered at high enough risk for an extra dose.